Another Phase I trial used HuMax-IL8 (BMS-986253; NCT02536469), an anti-IL-8 monoclonal antibody, in patients with metastatic or unresectable solid tumours, including PCa. This evidence concerns the gene CXCL8 and posterior cortical atrophy.